Jasper Therapeutics, Inc. (JSPR)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Ronald A. Martell | President, CEO & Director | 1.04M | -- | 1962 |
| Dr. Judith Anne Shizuru M.D., Ph.D. | Co-Founder, Member of Scientific Advisory Board & Director | 296.3k | -- | 1957 |
| Mr. Jeetinder Singh Mahal M.B.A. | Chief Operating Officer | 665.4k | -- | 1973 |
| Dr. Edwin Jonathan Tucker M.D. | Chief Medical Officer | 711.3k | -- | 1972 |
| Mr. David Ku M.D. | Vice President of Corporate Development, Portfolio Strategy & Management | -- | -- | -- |
| Mr. Matthew Ford | Senior Vice President of Human Resources | -- | -- | -- |
| Dr. Wendy Pang M.D., Ph.D. | Senior Vice President of Research & Translational Medicine | -- | -- | -- |
| Dr. Luca Di Noto Ph.D. | Senior Vice President of Technical Operations | -- | -- | -- |
| Ms. Patricia Carlos | Senior Vice President of Regulatory Affairs & Quality | -- | -- | -- |
| Ms. Kimberly Baxter | VP & Head of Quality | -- | -- | -- |
Jasper Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 64
Description
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
Corporate Governance
Upcoming Events
August 11, 2025 at 12:30 PM UTC - August 15, 2025 at 12:30 PM UTC
Jasper Therapeutics, Inc. Earnings Date
Recent Events
March 24, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission